Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2014

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.

Martin P, Dubois, et al. Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article Publication

Published 26 November 2014
Categorized as -others, 2014, Publication, TG1050

TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study

Elisabeth Quoix, et al. Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article Publication

Published 6 November 2014
Categorized as -others, 2014, Publication, TG4010

Transgene Announces Third Quarter 2014 Financial Results

266_en

Published 21 October 2014
Categorized as 2014, Press release

TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.

ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation

Published 30 September 2014
Categorized as -others, 2014, Publication, TG4010

Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010

261_en

Published 8 September 2014
Categorized as 2014, Press release, TG4010

Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.

Adrian Di Bisceglie, et al. Gastroenterology, 2014; Mar 18 – Download the article Publication

Published 1 July 2014
Categorized as -others, 2014, Publication, TG4040

Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.

Houda Boukhebza, et al. Vaccine. 2014, 32(26):3256-63. – Download the article Publication

Published 30 May 2014
Categorized as -others, 2014, Publication, TG1050

Transgene Reports First Quarter 2014 Financial Results

254_en

Published 22 April 2014
Categorized as 2014, Press release

Transgene Reports Fiscal Year 2013 Results and Provides Business Update

253_en

Published 26 March 2014
Categorized as 2014, Press release

Immunotherapy for non – small – cell lung cancer: current approaches.

Elisabeth Quoix, et al. Current Respiratory Care Reports, 2014; 3 (1): 19-25 – Download the article Publication

Published 31 January 2014
Categorized as -others, 2014, Publication, TG4010
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu